DNA Damage and Repair Biomarkers of Immunotherapy Response.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Discovery

• Publication date

  2017-06-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-17-0226PMID 28630051PMCID PMC5659200
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas

  2017cited by this paper
• Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

  2017cited by this paper
• PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

  2017influential reference
• Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

  2017cited by this paper
• Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

  2017cited by this paper
• Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

  2017cited by this paper
• Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

  2016cited by this paper
• Current clinical trials testing the combination of immunotherapy with radiotherapy

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• The unfolded protein response in immunity and inflammation

  2016cited by this paper
• Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.

  2016cited by this paper
• Cancer Immunology: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

  2016cited by this paper
• Mutational signatures associated with tobacco smoking in human cancer

  2016cited by this paper
• Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.

  2016cited by this paper
• Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations

  2016cited by this paper
• Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

  2016cited by this paper
• Abstract LB-264: Landscape of tumor-infiltrating T-cell repertoire of human cancers

  2016cited by this paper
• Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.

  2016cited by this paper
• Landscape of somatic mutations in 560 breast cancer whole genome sequences

  2016cited by this paper
• Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

  2016cited by this paper
• Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer

  2016cited by this paper
• Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents

  2016cited by this paper
• Nivolumab for recurrent squamous-cell carcinoma of the head and neck

  2016cited by this paper
• Immunogenic cell death in cancer and infectious disease

  2016cited by this paper
• Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.

  2016cited by this paper
• Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

  2016cited by this paper
• Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

  2016cited by this paper
• Repair Pathway Choices and Consequences at the Double-Strand Break.

  2016cited by this paper
• Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.

  2016cited by this paper
• Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

  2016cited by this paper
• Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing

  2016cited by this paper
• Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

  2016cited by this paper
• Cre-dependent DNA recombination activates a STING-dependent innate immune response

  2016cited by this paper
• Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

  2016cited by this paper
• Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells.

  2016cited by this paper
• Comprehensive analyses of tumor immunity: implications for cancer immunotherapy

  2016cited by this paper
• Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

  2016cited by this paper
• BRCAness revisited

  2016cited by this paper
• Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

  2016cited by this paper
• Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

  2016cited by this paper
• Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

  2016cited by this paper
• Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.

  2016cited by this paper
• Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.

  2016cited by this paper
• A panoply of errors: polymerase proofreading domain mutations in cancer

  2016cited by this paper
• Acquired resistance to immunotherapy and future challenges

  2016cited by this paper
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

  2016cited by this paper
• STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.

  2016cited by this paper
• Neoantigens in cancer immunotherapy

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity

  2015cited by this paper
• Immune checkpoint blockade: a common denominator approach to cancer therapy.

  2015cited by this paper
• IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells

  2015cited by this paper
• STING: infection, inflammation and cancer

  2015cited by this paper
• CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer

  2015cited by this paper
• Molecular and genetic properties of tumors associated with local immune cytolytic activity.

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

  2015cited by this paper
• POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

  2015cited by this paper
• Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

  2015cited by this paper
• DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity.

  2015cited by this paper
• Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

  2015cited by this paper
• Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.

  2015cited by this paper
• Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

  2015cited by this paper
• DNA damage in cancer therapeutics: a boon or a curse?

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.

  2015cited by this paper
• Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.

  2015cited by this paper
• Adenoma development in familial adenomatous polyposis and MUTYH‐associated polyposis: somatic landscape and driver genes

  2015cited by this paper
• Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes

  2015cited by this paper
• Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

  2015cited by this paper
• A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.

  2015cited by this paper
• DNA repair, genome stability and cancer: a historical perspective

  2015cited by this paper
• Mutant MHC class II epitopes drive therapeutic immune responses to cancer

  2015cited by this paper
• The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

  2015influential reference
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer.

  2015cited by this paper
• Targeting the DNA Damage Response in Cancer.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab

  2015cited by this paper
• Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.

  2015cited by this paper
• Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

  2015cited by this paper
• Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy.

  2015cited by this paper
• Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice

  2015cited by this paper
• DNA damage and the balance between survival and death in cancer biology

  2015cited by this paper
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer

  2015cited by this paper
• Whole–genome characterization of chemoresistant ovarian cancer

  2015cited by this paper
• Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer

  2014cited by this paper
• Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

  2014cited by this paper
• Discovery and saturation analysis of cancer genes across 21 tumor types

  2014cited by this paper
• Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

  2014cited by this paper
• High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

  2014cited by this paper
• Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

  2014cited by this paper
• Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

  2014cited by this paper
• Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

  2014cited by this paper
• Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

  2014cited by this paper

• NImmuno-radiobiology: Effects of radiation therapy on immune cells, tumor microenvironment, susceptibility of tumor cells to immune-mediated destruction, and anti-tumor immunity.

  2026cites this paper
• Synergistic effects of radiotherapy and immunotherapy: improving oncological outcomes.

  2026cites this paper
• Construction of a DNA damage response-related signature for prognostication and therapeutic response prediction in head and neck squamous cell carcinoma.

  2026cites this paper
• Intratumoral microbiota-based designing strategies for precision cancer therapeutics

  2026cites this paper
• UVB-Induced Genotoxic Stress Activates the DNA Damage Response and Innate Immune Pathways in Sea Urchin Coelomocytes

  2026cites this paper
• LIG1 overexpression enhances DNA repair and immune escape leading to poor prognosis in osteosarcoma

  2025cites this paper
• Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies

  2025cites this paper
• Aloperine exerts anti-tumor effect and activates the tumor cell-intrinsic STING pathway in gallbladder cancer.

  2025cites this paper
• Beyond proofreading: POLD1 mutations as dynamic orchestrators of genomic instability and immune evasion in cancer

  2025cites this paper
• Implications of DNA damage response and immunotherapy in tumor therapy

  2025cites this paper
• Exploring replication stress and cellular senescence as key targets in novel cancer therapies.

  2025cites this paper
• Systems Immunology Meets Clinical Translation: Multi-Omic Approaches to Predict Therapy Response in Cancer and Autoimmune Disease

  2025cites this paper
• Research progress on the induction of immunogenic cell death in tumor immunotherapy using a sonodynamic therapy nanoparticle delivery system

  2025influential citation
• UVC-Induced Oxidative Stress and DNA Damage Repair Status in Head and Neck Squamous Cell Carcinoma Patients with Different Responses to Nivolumab Therapy

  2025cites this paper
• Safety and toxicity risks of radiotherapy combined with PD-1/PD-L1 inhibitors: A comprehensive review

  2025cites this paper
• Radiotherapy as salvage therapy and an adjunct to immunotherapy: exploring local and abscopal mechanisms to overcome immunotherapy resistance: a narrative review

  2025cites this paper
• DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer

  2025cites this paper
• Hydrogels as drug delivery platforms for orthopedic diseases treatment: A review.

  2025cites this paper
• Anti-galectin-9 therapy synergizes with EGFR inhibition to reprogram the tumor microenvironment and overcome immune evasion

  2025cites this paper
• Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage.

  2025cites this paper
• Molecular classification of microsatellite-instable colorectal cancers reveals distinct predictors of immunotherapy response

  2025influential citation
• PARP7 Suppresses Radiation-induced Necroptosis and Abscopal Immunity

  2025cites this paper
• The cold immunological landscape of ATM-deficient cancers

  2025cites this paper
• Механизмы резистентности к иммунотерапии при MSI фенотипе

  2025cites this paper
• Post-translational modifications of proteins: dynamic regulatory network and therapeutic targets of tumor immune escape in pan-cancer.

  2025cites this paper
• Theranostic potential of manganese dioxide nanoparticles for targeting tumor hypoxia during MR-guided radiotherapy.

  2025cites this paper
• Computational microbiome pharmacology analysis elucidates the anti-cancer potential of vaginal microbes and metabolites

  2025cites this paper
• Translational Aspects of DNA Damage Repair in Optimizing Cancer Chemotherapy

  2025cites this paper
• The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers

  2025cites this paper
• Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy

  2025cites this paper
• Elucidating DNA Damage-Dependent Immune System Activation

  2025cites this paper
• Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application

  2025cites this paper
• Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors

  2025cites this paper
• Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes

  2025cites this paper
• Effects of immune related adverse events and corticosteroids on the outcome of patients treated with immune checkpoint inhibitors

  2025cites this paper
• Advances in the relationship of immune checkpoint inhibitors and DNA damage repair.

  2025cites this paper
• PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024

  2025cites this paper
• A Novel DNA Repair‐Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients With EGFR‐Mutant Non‐Small Cell Lung Cancer

  2025cites this paper
• Targeting DNA Damage Repair to Enhance Antitumor Immunity in Radiotherapy: Mechanisms and Opportunities

  2025cites this paper
• Designing a multi-neoantigen vaccine for melanoma: Integrating immunoinformatics and biophysics methods

  2025cites this paper
• Association of DNA damage response signals and oxidative stress status with nivolumab efficacy in patients with Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer.

  2025cites this paper
• Tumor irradiation induced immunogenic response: the impact of DNA damage induction and misrepair

  2025cites this paper
• Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities

  2025cites this paper
• Humic acid enhances adsorption of antibiotic ciprofloxacin on polylactic acid microplastics, leading to reproductive and mitochondrial toxicity in Daphnia magna: Quantitative analysis.

  2025cites this paper
• Discovery of novel thiosemicarbazone dimers as effective inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) for use in cancer therapy.

  2025cites this paper
• Development of a quantitative genomic instability scoring system and a related competing endogenous RNA network in head and neck squamous cell carcinoma

  2025cites this paper
• Bazedoxifene analogs as potential WDHD1 degraders and antitumor agents: Synthesis, evaluation and molecular dynamics simulation studies

  2024cites this paper
• Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab

  2024cites this paper
• Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage.

  2024cites this paper
• Dynamic change of cancer genome profiling in metachronous bilateral breast cancer with BRCA pathogenic variant

  2024cites this paper
• Chiral coordination polymer nanowires boost radiation-induced in situ tumor vaccination

  2024cites this paper
• Nrf2: A key regulator in chemoradiotherapy resistance of osteosarcoma

  2024cites this paper
• The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and Cadonilimab for locally advanced rectal cancer: a protocol of a phase II study

  2024cites this paper
• Methylated lncRNAs suppress apoptosis of gastric cancer stem cells via the lncRNA–miRNA/protein axis

  2024cites this paper
• The immune response-related genomic alterations in patients with malignant melanoma

  2024cites this paper
• RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer

  2024cites this paper
• A Novel Inhibitor of Poly(ADP-Ribose) Polymerase-1 Inhibits Proliferation of a BRCA-Deficient Breast Cancer Cell Line via the DNA Damage-Activated cGAS-STING Pathway.

  2024cites this paper
• Enzyme‐Empowered “Two Birds with One Stone” Strategy for Amplifying Tumor Apoptosis and Metabolic Clearance

  2024cites this paper
• Immunologic tumor microenvironment modulators for turning cold tumors hot

  2024cites this paper
• Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

  2024cites this paper
• P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation

  2024cites this paper
• Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors

  2024cites this paper
• Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?

  2024cites this paper
• Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group

  2024cites this paper
• Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes.

  2024cites this paper
• Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors

  2024cites this paper
• Multi-omic analyses of m5C readers reveal their characteristics and immunotherapeutic proficiency

  2024cites this paper
• ssMutPA: single-sample mutation-based pathway analysis approach for cancer precision medicine

  2024cites this paper
• Multilevel Mechanisms of Cancer Drug Resistance

  2024cites this paper
• The evaluation of cyclin D1 expression in prostate carcinoma cases

  2024cites this paper
• Tumor organoids improve mutation detection of pancreatic ductal adenocarcinoma

  2024cites this paper
• Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects

  2024cites this paper
• Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929.

  2024cites this paper
• Advances in Immune Checkpoint Therapy in Hepatocellular Carcinoma.

  2024cites this paper
• Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature

  2024cites this paper
• Personalized treatment approach for HER2-positive metastatic breast cancer

  2024cites this paper
• The Therapeutic Potential of Targeting Tumor Microenvironment and Modulation of Immunotherapy in Gastrointestinal Cancer.

  2024cites this paper
• Re-irradiation plus pembrolizumab: Phase II study for recurrent glioblastoma patients.

  2024cites this paper
• Landscape of homologous recombination deficiency in gastric cancer and clinical implications for first-line chemotherapy

  2024cites this paper
• Homologous recombination deficiency status predicts response to immunotherapy‐based treatment in non‐small cell lung cancer patients

  2024cites this paper
• PD-L1 deglycosylation promotes its nuclear translocation and accelerates DNA double-strand-break repair in cancer

  2024cites this paper
• Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer

  2024cites this paper
• Illuminating immunotherapy response via precision T cell-targeted PET imaging

  2024influential citation
• Predictive value of serum alkaline phosphatase, tumor-specific growth factor, and macrophage migration inhibitory factor for the efficacy of immunotargeted therapy in osteosarcoma patients.

  2024cites this paper
• Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer

  2024cites this paper
• ATM, BLM, and CDH1 gene co-mutations in a high-grade endometrial stromal sarcoma patient with multiple abdominal cavity metastases: a case report and literature review

  2024cites this paper
• Dynamic immunoediting by macrophages in homologous recombination deficiency-stratified pancreatic ductal adenocarcinoma.

  2024cites this paper
• Preoperative short‐course radiotherapy followed by chemotherapy and PD‐1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study)

  2024cites this paper
• Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair

  2024cites this paper
• Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment

  2024cites this paper
• Identification of a prognostic DNA repair gene signature in esophageal cancer

  2024cites this paper
• Nano-enabled regulation of DNA damage in tumor cells to enhance neoantigen-based pancreatic cancer immunotherapy.

  2024cites this paper
• Inflammation-related markers and prognosis of alpha-fetoprotein producing gastric cancer

  2024cites this paper
• A novel DNA damage repair gene-related prognostic model for evaluating the prognosis and tumor microenvironment infiltration of esophageal squamous cell carcinoma

  2023cites this paper
• New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination

  2023cites this paper
• DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining Immunotherapy

  2023cites this paper
• Identification and Analysis of Hub Genes and Immune Cells Associated with the Formation of Acute Aortic Dissection

  2023cites this paper
• Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study

  2023cites this paper
• Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer

  2023cites this paper